For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 60,819 | 49,889* | 54,178 | 55,703 |
| General and administrative | 21,953 | 19,040* | 17,100 | 17,462 |
| Total operating expenses | 82,772 | 68,929 | 71,278 | 73,165 |
| Loss from operations | -82,772 | -68,929* | -71,278 | -73,165 |
| Interest income, net | 8,740 | 9,842 | 6,318 | 7,141 |
| Total other income, net | 8,740 | 9,842* | 6,318 | 7,141 |
| Net loss before taxes | -74,032 | -59,088* | -64,960 | -66,024 |
| Provision for income taxes | 79 | 79* | 61 | 72 |
| Net loss after taxes | -74,111 | -59,167 | -65,021 | -66,096 |
| Basic EPS | -1.06 | -0.912 | -1.11 | -1.13 |
| Diluted EPS | -1.06 | -0.912 | -1.11 | -1.13 |
| Basic Average Shares | 69,668,439 | 64,870,385 | 58,773,731 | 58,428,344 |
| Diluted Average Shares | 69,668,439 | 64,870,385 | 58,773,731 | 58,428,344 |
Apogee Therapeutics, Inc. (APGE)
Apogee Therapeutics, Inc. (APGE)